Broadcom, AT&T, Vertex Pharma Stocks Highlighted in Zacks Analyst Blog

Semiconductor, telecom and biotech firms navigate opportunities and risks in latest research reports.

Published on Mar. 4, 2026

Got story updates? Submit your updates here. ›

The Zacks Analyst Blog featured new research reports on major stocks like Broadcom Inc., AT&T Inc. and Vertex Pharmaceuticals Inc., as well as the microcap company The InterGroup Corp. The reports highlighted key trends and challenges facing these firms, including Broadcom's momentum in AI chips, AT&T's fiber expansion and wireless growth, Vertex's cystic fibrosis drug sales, and InterGroup's hotel asset performance.

Why it matters

The Zacks Analyst Blog provides in-depth analysis on major public companies, offering investors insights into the opportunities and risks facing these firms. The featured research covers a diverse range of industries, from semiconductors to telecommunications to pharmaceuticals, giving a broad perspective on the state of the market.

The details

The Zacks research reports delved into the latest developments for each company. For Broadcom, the focus was on strong demand for its AI chips and networking products, though gross margins are expected to contract. AT&T was highlighted for its wireless growth and fiber expansion plans, though its wireline business continues to struggle. Vertex Pharmaceuticals saw sales growth for its cystic fibrosis drugs, but also pipeline setbacks and slower-than-expected uptake of newer products. The microcap InterGroup benefited from improved hotel performance and asset sales, though leverage and concentration risks remain.

  • The Zacks Analyst Blog reports were published on March 4, 2026.

The players

Broadcom Inc.

A leading semiconductor company that provides a range of infrastructure software and semiconductor solutions.

AT&T Inc.

A major telecommunications company providing wireless, broadband, and entertainment services.

Vertex Pharmaceuticals Inc.

A biotechnology company focused on developing and commercializing therapies for serious diseases, particularly cystic fibrosis.

The InterGroup Corp.

A microcap real estate development and hotel management company, primarily focused on a flagship hotel property in San Francisco.

Got photos? Submit your photos here. ›

The takeaway

The Zacks Analyst Blog provides valuable insights into the latest developments and outlooks for major public companies across diverse industries. The featured research highlights both the opportunities and challenges facing firms like Broadcom, AT&T, Vertex Pharmaceuticals, and InterGroup, giving investors a more comprehensive view of the market landscape.